

C1129	12	2.2	15	1	AA152130	Human ICAM hammer
C1130	12	2.2	15	1	AA16990	HLA sequence 29.
C1131	12	2.2	15	1	AA157003	Human Notch3 gene
C1132	12	2.2	15	1	AA158221	Tumour antigen ant
C1133	12	2.2	15	1	AA159018	PCR primer H-T11a
C1134	12	2.2	15	1	AA167276	Human FKBP8 allele
C1135	12	2.2	15	1	AA171747	PCR primer #2. Sy
C1136	12	2.2	15	1	AA155207	Genomic DNA methyl
C1137	12	2.2	15	1	AA155208	Genomic DNA methyl
C1138	12	2.2	15	1	AA155211	Genomic DNA methyl
C1139	12	2.2	15	1	AA155212	Dye-labeled didox
C1140	12	2.2	15	1	AA155217	Dye-labeled molecul
C1141	12	2.2	15	1	AA155219	IGFBP3 oligonucleo
C1142	12	2.2	15	1	AA155225	IGFBP3 oligonucleo
C1143	12	2.2	15	1	AA155226	IGFBP3 oligonucleo
C1144	12	2.2	15	1	AA155229	IGFBP3 oligonucleo
C1145	12	2.2	15	1	AA155230	IGFBP3 oligonucleo
C1146	12	2.2	15	1	AA155231	IGFBP3 oligonucleo
C1147	12	2.2	15	1	AA155232	IGFBP3 oligonucleo
C1148	12	2.2	15	1	AA155233	IGFBP3 oligonucleo
C1149	12	2.2	15	1	AA155234	IGFBP3 oligonucleo
C1150	12	2.2	15	1	AA155235	IGFBP3 oligonucleo
C1151	12	2.2	15	1	AA155236	IGFBP3 oligonucleo
C1152	12	2.2	15	1	AA155237	IGFBP3 oligonucleo
C1153	12	2.2	15	1	AA155238	IGFBP3 oligonucleo
C1154	12	2.2	15	1	AA155239	IGFBP3 oligonucleo

## ALIGNMENTS

RESULT 1  
ABZ00175  
ID ABZ00175 standard, DNA, 50 BP.

AC ABZ00175;  
DT 09-JAN-2003 (first entry)

DE Human leukocyte gene expression profiling probe SEQ ID NO. 166.  
XX  
XX T7, leukocyte; gene expression profiling; allograft rejection;  
KM atherosclerosis; congestive heart failure; systemic lupus erythematosus;  
KM rheumatoid arthritis; osteoarthritis; cytomegalovirus; infection;  
KM probe; ss.

OS Homo sapiens.  
PN WO200257414-A2.  
PD 25-JUL-2002.  
PF 22-OCT-2001; 2001WO-US47856.  
PR 20-OCT-2000; 2000US-241994P.  
PR 08-JUN-2001; 2001US-296764P.

XX (BIOC-) BIOCARDIA INC.

PI Wohlgemuth J, Fry K, Marcuk G, Altman P, Prentice J, Phillips J;  
PI Ly N, Woodward R, Quertermous T, Johnson F;  
DR WF; 2002-636525/68.

XX New system for leukocyte expression profiling, diagnosing a disease, or  
PT monitoring (the rate of) progression of a disease, e.g. atherosclerosis  
PT or congestive heart failure, comprises diagnostic oligonucleotides -  
XX Claim 1; Page 332; 2038bp; English.

CC The invention relates to a system for detecting gene expression, which  
CC comprises one or two isolated DNA molecules that detect expression of a  
CC gene, where the gene corresponds to any of 8143 oligonucleotides

(ABZ00010-ABZ00152) each having 50 base pairs (bp). The system is useful  
CC for leukocyte expression profiling. It is particularly useful for  
CC diagnosing a disease, monitoring (rate of) progression of a disease,  
CC predicting therapeutic outcome, determining prognosis for a patient,  
CC predicting disease complications in an individual or monitoring response  
CC to treatment in an individual. The diseases include cardiac allograft  
CC rejection, kidney allograft rejection, liver allograft rejection,  
CC atherosclerosis, congestive heart failure, systemic lupus erythematosus,  
CC rheumatoid arthritis, osteoarthritis or cytomegalovirus infection.  
XX  
SQ Sequence 50 BP; 11 A; 18 C; 6 G; 15 T; 0 other;

Query Match 9.3%; Score 50; DB 1; Length 50;  
Best Local Similarity 100.0%; Pred. No. 0.00018;  
Matches 50; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1385 GCCTTATGACCTGCTCTTCAACACGCTCCCTTCAACTATACCA 1434  
DB 1 GCCTTATGACCTGCTCTTCAACACGCTCCCTTCAACTATACCA 50

RESULT 2  
ABZ04679  
ID ABZ04679 standard, DNA, 50 BP.

AC ABZ04679;

DT 09-JAN-2003 (first entry)

DE Human leukocyte gene expression profiling probe SEQ ID NO. 4670.

XX  
XX T7, leukocyte; gene expression profiling; allograft rejection;  
KM atherosclerosis; congestive heart failure; systemic lupus erythematosus;  
KM rheumatoid arthritis; osteoarthritis; cytomegalovirus; infection;  
KM probe; ss.

OS Homo sapiens.  
PN WO200257414-A2.  
PD 25-JUL-2002.  
PF 22-OCT-2001; 2001WO-US47856.  
PR 20-OCT-2000; 2000US-241994P.  
PR 08-JUN-2001; 2001US-296764P.

XX (BIOC-) BIOCARDIA INC.

PI Wohlgemuth J, Fry K, Marcuk G, Altman P, Prentice J, Phillips J;  
PI Ly N, Woodward R, Quertermous T, Johnson F;  
DR WF; 2002-636525/68.

XX New system for leukocyte expression profiling, diagnosing a disease, or  
PT monitoring (the rate of) progression of a disease, e.g. atherosclerosis  
PT or congestive heart failure, comprises diagnostic oligonucleotides -  
XX Claim 1; Page 477; 2038bp; English.

CC The invention relates to a system for detecting gene expression, which  
CC comprises one or two isolated DNA molecules that detect expression of a  
CC gene, where the gene corresponds to any of 8143 oligonucleotides  
CC (ABZ00010-ABZ00152) each having 50 base pairs (bp). The system is useful  
CC for leukocyte expression profiling. It is particularly useful for  
CC diagnosing a disease, monitoring (rate of) progression of a disease,  
CC predicting therapeutic outcome, determining prognosis for a patient,  
CC predicting disease complications in an individual or monitoring response  
CC to treatment in an individual. The diseases include cardiac allograft  
CC rejection, kidney allograft rejection, liver allograft rejection,  
CC atherosclerosis, congestive heart failure, systemic lupus erythematosus,  
CC rheumatoid arthritis, osteoarthritis or cytomegalovirus infection.

AT-ACHMAM7

COPY

SQ Sequence 50 BP; 13 A; 17 C; 5 G; 15 T; 0 other;

Query Match 9.3%; Score 50; DB 1; Length 50;  
Best Local Similarity 100.0%; Pred. No. 0.00018;  
Matches 50; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1404 TTCTACAGTCGCTTCACTGTATACACACATCTGATCGTCATT 1453  
1 TTCTACAGTCGCTTCACTGTATACACACATCTGATCGTCATT 50

RESULT 3

AAH88905  
ID AAH88905 standard; DNA; 21 BP.

AC AAH88905;

DT 27-FEB-2002 (first entry)

DE Human polymorphic oligonucleotide AC003693 fragment #1.

KM Human; single nucleotide polymorphic; SNP; forensic science;

KM paternity testing; phenotypic trait; genetic mapping; animal breeding;

OS Homo sapiens.

Key Location/Qualifiers

FT Variation replace(11,G)

FT /\*tag= a /standard\_name= "single nucleotide polymorphism"

PN WO200134840-A2.

PD 17-MAY-2001.

PF 10-NOV-2000; 2000WO-US30766.

PR 10-NOV-1999; 99US-0164596.

PA (GLAXO) GLAXO GROUP LTD.

PA (AFRY-) AFRYMETRIX INC.

PI Au K, Chen J, Patil N, Thomas D;

DR WPI; 2001-335945/35.

PT New polymorphic sites derived from the human genome are useful to  
determine sites correlating with phenotypic traits, particularly  
disease, and also in forensics and paternity testing -

PS Claim 37; Page 9; 43pp; English.

CC The present invention relates to human oligonucleotides comprising a  
single nucleotide polymorphic site (SNP: AAH88797-AAH89219). The present  
sequence is one such oligonucleotide. The oligonucleotides can be used in  
forensics, paternity testing, correlation of polymorphisms with  
phenotypic traits, genetic mapping of phenotypic traits and marker  
assisted breeding of animals and crop plants.

SQ Sequence 21 BP; 4 A; 8 C; 5 G; 4 T; 0 other;

Query Match 3.9%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 28;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 979 TGCAGTGGCCCTTAGTGACC 999

Db 1 TGCAGTGGCCCTTAGTGACC 21

RESULT 4  
AAH88906

ID AAH88906 standard; DNA; 21 BP.

AC AAH88906;

DT 27-FEB-2002 (first entry)

DE Human polymorphic oligonucleotide AC003693 fragment #2.

KM Human; single nucleotide polymorphic; SNP; forensic science;

KM paternity testing; phenotypic trait; genetic mapping; animal breeding;

OS Homo sapiens.

Key Location/Qualifiers

FT Variation replace(11,T)

FT /\*tag= a /standard\_name= "single nucleotide polymorphism"

PN WO200134840-A2.

PD 17-MAY-2001.

PF 10-NOV-2000; 2000WO-US30766.

PR 10-NOV-1999; 99US-0164596.

PA (GLAXO) GLAXO GROUP LTD.

PA (AFRY-) AFRYMETRIX INC.

PI Au K, Chen J, Patil N, Thomas D;

DR WPI; 2001-335945/35.

PT New polymorphic sites derived from the human genome are useful to  
determine sites correlating with phenotypic traits, particularly  
disease, and also in forensics and paternity testing -

PS Claim 37; Page 9; 43pp; English.

CC The present invention relates to human oligonucleotides comprising a  
single nucleotide polymorphic site (SNP: AAH8797-AAH89219). The present  
sequence is one such oligonucleotide. The oligonucleotides can be used in  
forensics, paternity testing, correlation of polymorphisms with  
phenotypic traits, genetic mapping of phenotypic traits and marker  
assisted breeding of animals and crop plants.

SQ Sequence 21 BP; 5 A; 5 C; 3 G; 8 T; 0 other;

Query Match 3.9%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 28;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1036 ATACGTTCCGGTATTACTC 1056

Db 1 ATACGTTCCGGTATTACTC 21

RESULT 5

AAH88905  
ID AAH88905 standard; DNA; 25 BP.

AC AAH88905;

DT 26-FEB-2001 (first entry)

DE HLA DPB1 gene PCR primer #77.

KM DNA sequence analysis; sequencing; protein sequence; protein structure;  
KM gene typing; organ donation; bacteria identification; 16S rRNA; HLA;  
KM human leukocyte antigen; PCR primer; ss.

OS Homo sapiens.

```

XX WO200065088-A2.
XX
XX 02-NOV-2000.
XX
XX 20-APR-2000; 2000WO-EP03636.
XX
XX 26-APR-1999; 99EP-0303215.
XX
XX (AMSH ) AMERSHAM PHARMACIA BIOTECH AB.
XX
XX Ulfendahl P, Wong K;
XX
XX WPI; 2000-679677/66.
XX
XX Identifying extendible primers for use in identification, or
XX classification of a nucleic acid of an organism, allele or gene such as
XX PT class 1/2 HLA comprises identifying all possible nucleotide sequences
XX PT of specific length -
XX
XX PS Claim 14; Page 49; 66pp; English.
XX
XX The present invention provides a method for identifying a set of
XX CC extendible primers which can be used in the identification, typing and
XX CC classification of genes. This can then be used to predict protein
XX CC sequence and structure, in organ donation to match the organ with the
XX CC receiver, and to identify bacteria in a sample. The method can be used to
XX CC type the human leukocyte antigen genes (HLA) and 16S rRNA genes in
XX CC particular.
XX
XX Sequence 25 BP; 2 A; 5 C; 3 G; 15 T; 0 other;
XX
XX Query Match 3.8%; Score 20.4; DB 1; Length 25;
XX Best Local Similarity 95.5%; Pred. No. 66;
XX Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 1471 CAGGCATGCTAAAAAAA 1492
XX DB 22 CAGGAATGCTAAAAAAA 1
XX
XX RESULT 6
XX AAQ75716/c
XX ID AAQ75716 standard; DNA; 21 BP.
XX
XX AC AAQ75716;
XX
XX 04-AUG-1995 (first entry)
XX
XX Reverse transcription primer used in cDNA analysis technique.
XX
XX Analysis; gene expression; reverse transcription; primer; cDNA;
XX KM aggregate; restriction enzyme; ss.
XX
XX Synthetic.
XX
XX JP06303997-A.
XX
XX 01-NOV-1994.
XX
XX 16-APR-1993; 93JP-0112515.
XX
XX 16-APR-1993; 93JP-0112515.
XX
XX (NITE ) NIPPON TELEGRAPH & TELEPHONE CORP.
XX
XX WPI; 1995-018287/03.
XX
XX Analysis of cDNA and gene expression - by amplification of mRNA
XX PT followed by digestion with restriction enzymes
XX
XX Disclosure; Page 8; 11pp; Japanese.
XX

```

```

CC A method for the analysis of cDNA comprises (a) preparing an
CC aggregate of double-stranded cDNAs by using an aggregate of mRNAs
CC and a plural type of labelled reverse transcription primers
CC (GENESBQ files AAQ75547-075798) and using the aggregate of mRNAs as the
CC template for each reverse transcription primer; (b) digesting each of
CC the prepared aggregates of the double-stranded cDNAs with restriction
CC enzyme and; (c) electrophoresing the digested aggregate of cDNAs in
CC separate lanes. The method can be used to analyse gene expression
CC rapidly and easily.
XX
XX Sequence 21 BP; 2 A; 1 C; 1 G; 17 T; 0 other;
XX
XX Query Match 3.7%; Score 20; DB 1; Length 21;
XX Best Local Similarity 100.0%; Pred. No. 47;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1477 TGCTAAAAAAA 1496
XX DB 21 TGCTAAAAAAA 2
XX
XX RESULT 7
XX AAQ75661/c
XX ID AAQ75661 standard; DNA; 21 BP.
XX
XX AC AAQ75661;
XX
XX 04-AUG-1995 (first entry)
XX
XX Reverse transcription primer used in cDNA analysis technique.
XX
XX Analysis; gene expression; reverse transcription; primer; cDNA;
XX KM aggregate; restriction enzyme; ss.
XX
XX Synthetic.
XX
XX JP06303997-A.
XX
XX 01-NOV-1994.
XX
XX 16-APR-1993; 93JP-0112515.
XX
XX 16-APR-1993; 93JP-0112515.
XX
XX (NITE ) NIPPON TELEGRAPH & TELEPHONE CORP.
XX
XX WPI; 1995-018287/03.
XX
XX Analysis of cDNA and gene expression - by amplification of mRNA
XX PT followed by digestion with restriction enzymes
XX
XX Disclosure; Page 6; 11pp; Japanese.
XX
XX A method for the analysis of cDNA comprises (a) preparing an
XX CC aggregate of double-stranded cDNAs by using an aggregate of mRNAs
XX CC and a plural type of labelled reverse transcription primers
XX CC (GENESBQ files AAQ75547-075798) and using the aggregate of mRNAs as the
XX CC template for each reverse transcription primer; (b) digesting each of
XX CC the prepared aggregates of the double-stranded cDNAs with restriction
XX CC enzyme and; (c) electrophoresing the digested aggregate of cDNAs in
XX CC separate lanes. The method can be used to analyse gene expression
XX CC rapidly and easily.
XX
XX Sequence 21 BP; 1 A; 1 C; 1 G; 18 T; 0 other;
XX
XX Query Match 3.6%; Score 19.4; DB 1; Length 21;
XX Best Local Similarity 95.2%; Pred. No. 63;
XX Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 1476 ATGCTAAAAAAA 1496
XX DB 21 ATGCAAAAAAAA 1
XX

```

```

XX RESULT 8
XX AAQ49436/c
XX ID AAQ49436 standard; cDNA; 20 BP.
XX
XX AC AAQ49436;
XX
XX DT 25-MAR-2003 (updated)
XX DT 27-APR-1994 (first entry)
XX
XX DE Cytochrome P450 sequence amplification PCR primer polyT.
XX
XX KM Transgenic plants; altered petal colour;
XX KM polymerase chain reaction; ss.
XX
XX OS Synthetic.
XX
XX PN WO9320206-A1.
XX
XX PD 14-OCT-1993.
XX
XX PF 25-MAR-1993; 93WO-AU00127.
XX
XX PR 27-MAR-1992; 92AU-0001538.
XX PR 07-JAN-1993; 93AU-0006698.
XX
XX PA (ITFL-) INT FLOWER DEV PTY LTD.
XX
XX PI Cornish EC, Holton TA, Tanaka Y;
XX
XX DR WPI; 1993-336914/42.
XX
XX PT Nucleic acid isolate encoding flavonoid-3'-hydroxylase - is used to
XX PT create transgenic plants with altered petal colour
XX
XX PS Disclosure; Page 25; 86pp; English.
XX
XX CC The sequence is that of a PCR primer which was used in polymerase
XX CC chain reactions for the amplification of cloned cytochrome P450
XX CC sequences.
XX CC (Updated on 25-MAR-2003 to correct PN field.)
XX
XX SQ Sequence 20 BP; 1 A; 1 C; 1 G; 17 T; 0 other;
XX
XX Query Match 3.5%; Score 19; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 66;
XX Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1478 GCTAAAAAAAAAAAAA 1496
XX
XX DB 20 GCTAAAAAAAAAAAAA 2
XX
XX RESULT 9
XX AAQ7578/c
XX ID AAQ7578 standard; DNA; 20 BP.
XX
XX AC AAQ7578;
XX
XX DT 04-AUG-1995 (first entry)
XX
XX DE Reverse transcription primer used in cDNA analysis technique.
XX
XX KM Analysis; gene expression; reverse transcription; primer; cDNA;
XX KM aggregate; restriction enzyme; ss.
XX
XX OS Synthetic.
XX
XX PN JP06303997-A.
XX
XX PD 01-NOV-1994.
XX
XX PF 16-APR-1993; 93JP-0112515.
XX
XX PR 16-APR-1993; 93JP-0112515.
XX
XX PA (NITE ) NIPPON TELEGRAPH & TELEPHONE CORP.
XX
XX DR WPI; 1995-018287/03.
XX
XX PT Analysis of cDNA and gene expression - by amplification of mRNA
XX PT followed by digestion with restriction enzymes
XX
XX PS Disclosure; Page 5; 11pp; Japanese.
XX
XX CC A method for the analysis of cDNA comprises (a) preparing an
XX CC aggregate of double-stranded cDNAs by using an aggregate of mRNAs
XX CC and a plural type of labelled reverse transcription primers
XX CC (GENESQ files AAQ75547-Q75798) and using the aggregate of mRNAs as the
XX CC template for each reverse transcription primer; (b) digesting each of
XX CC the prepared aggregates of the double-stranded cDNAs with restriction
XX CC enzyme and; (c) electrophoresing the digested aggregate of cDNAs in
XX CC separate lanes. The method can be used to analyse gene expression
XX CC rapidly and easily.
XX
XX SQ Sequence 20 BP; 1 A; 1 C; 1 G; 17 T; 0 other;
XX
XX Query Match 3.5%; Score 19; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 66;
XX Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1478 GCTAAAAAAAAAAAAA 1496
XX
XX DB 20 GCTAAAAAAAAAAAAA 2
XX
XX RESULT 10
XX AAQ75715/c
XX ID AAQ75715 standard; DNA; 21 BP.
XX
XX AC AAQ75715;
XX
XX DT 04-AUG-1995 (first entry)
XX
XX DE Reverse transcription primer used in cDNA analysis technique.
XX
XX KM Analysis; gene expression; reverse transcription; primer; cDNA;
XX KM aggregate; restriction enzyme; ss.
XX
XX OS Synthetic.
XX
XX PN JP06303997-A.
XX
XX PD 01-NOV-1994.
XX
XX PF 16-APR-1993; 93JP-0112515.
XX
XX PR 16-APR-1993; 93JP-0112515.
XX
XX PA (NITE ) NIPPON TELEGRAPH & TELEPHONE CORP.
XX
XX DR WPI; 1995-018287/03.
XX
XX PT Analysis of cDNA and gene expression - by amplification of mRNA
XX PT followed by digestion with restriction enzymes
XX
XX PS Disclosure; Page 8; 11pp; Japanese.
XX
XX CC A method for the analysis of cDNA comprises (a) preparing an
XX CC aggregate of double-stranded cDNAs by using an aggregate of mRNAs
XX CC and a plural type of labelled reverse transcription primers
XX CC (GENESQ files AAQ75547-Q75798) and using the aggregate of mRNAs as the
XX CC template for each reverse transcription primer; (b) digesting each of
XX CC the prepared aggregates of the double-stranded cDNAs with restriction
XX CC enzyme and; (c) electrophoresing the digested aggregate of cDNAs in
XX CC separate lanes. The method can be used to analyse gene expression

```